Follow up of ovarian cancer after primary therapy;Surveillance des cancers de l'ovaire traites

Revue du Praticien

Volumn 47, Issue 11, 1997, Pages 1211-1215

  Pecking, Alain ^a   Pichon, Marie France ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

BLOOD; CANADA; CANCER GROWTH; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; OVARY CANCER; SHORT SURVEY;

CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 0030979901     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. NIH Consensus conference: Ovarian cancer: screening, treatment and follow up. JAMA 1995; 273: 491-7.
2. Grandberg S, Wikland M, Jansson I. Macroscopic characterisation of ovarian tumors and the relation to the histologic diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989; 35: 139-44.
3. Van Nagell J, De Priest P, Puls L et al. Ovarian cancer screening in asymptomatic postmenopausai women by transvaginal sonography. Cancer 1991; 68: 458-62.
4. Bourne T, Campbell S, Reynolds K et al. Screening of early familial ovarian cancer with transvaginal ultrasonography and color blood flow imaging. BMJ 1993; 306: 1025-9.
5. Goldenberg DM, Deland FH, Kim E et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-8.
6. Chatal JF, Fumoleau P, Saccavini JC et al. Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med 1987; 28: 1807-19.
7. 111In-CYT-103, Oncoscint OV 103) for the detection of epithelial ovarian carcinoma. Ant Immu Radiopharm 1990; 3: 44-56.
8. 131I-fragments of OC125 antibody. Clin Chem 1993; 39 (5): 891-6.
9. Stall KE, Martin EW. Plasma carcinoembryonic antigen levels in ovarian cancer patients: a chart review and summary of published data. J Reprod Med 1981; 26: 75-82.
10. Jacobs I, Bast R. The CA125 tumour associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12.
11. Bast RC, Klug TL, John ES et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
12. Zurawski V, Knapp R, Einhorn N et al. An initial analysis of preoperative serum CA125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988; 30: 7-14.
13. Schartz P, Chambers S, Chambers J et al. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer 1987; 60: 353-61.
14. Davidson NG, Khanna S, Kirwan P et al. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol 1991; 3: 32-6.
15. Redman CWE, Blackledge GR, Kelly K et al. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990; 26: 593-6.
16. Van den Burg ME, Lammes FB, Van Putten WL et al. Ovarian cancer: the prognostic value of the serum half life of CA125 during induction chemotherapy. Gynecol Obstet 1988; 30: 307-12.
17. Hogberg T, Kagedal B. Serum half life of the tumor marker CA125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423-9.
18. Hunter VJ, Daly L, Helms M et al. The prognostic significance of CA125 half life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990; 163: 1164-7.
19. Rosen A, Sevelda P, Klein M et al. A CA125 Score as a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 1990; 247: 125-9.
20. Einhorn N, Sjokall K, Knapp R et al. Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 1992; 80: 14-8.
21. Jacobs I, Prys Davies A, Bridges J et al. Prevalence screening for ovarian cancer in post-menopausal women by CA125 measurement and ultrasonography. BMJ 1993; 306: 1030-4.
22. Kenemans P, Vertraeten AA, Van Kamp GJ et al. The second generation CA125 Assays. Ann Med 1995; 27: 107-13.
23. Liefooghe J, Forzy G, Jannet M et al. Essai comparatif en routine de plusieurs méthodes de dosages des marqueurs tumoraux CA15.3, CA125 et CA19.9. Immun Biol Spe 1992; 31: 33-42.
24. Kacinski BM, Stanley R, Carter D et al. Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasm. Int J Radiat Oncol Biol Phys 1989; 17: 159-64.
25. Buller RE, Berman ML, Bloss JD et al. CA125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 1991; 165: 360-7.
26. Buller RE, Vasilev S, DiSaia PJ. CA125 kinetics: a cost effective clinical tool to evaluate clinical trial outcome in the 1990s. Obstet Gynecol 1996; 174: 1241-54.
27. Davelaar EM, Bonfrer JMG, Verstraeten RA et al. CA125: A valid marker in ovarian carcinoma patients treated with Paclitaxel. Cancer 1996; 78: 118-27.
28. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 1996; 14: 1545-51.